MIRM
Mirum Pharmaceuticals, Inc.
$100.90
+0.27
(+0.27%)
Mkt Cap
6.15B
Volume
350,960
52W Range
63.232-130
Sector
Healthcare
Beta
0.49
EPS (TTM)
-14.56 USD
P/E Ratio
-168.06
Revenue (TTM)
618.07M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 521.31M | 336.89M | 186.37M | 77.06M | 19.14M | 0 | 0 | 0 |
| Net Income | (23.36M) | (87.94M) | (163.41M) | (135.66M) | (83.99M) | (103.27M) | (52.55M) | (17.35M) |
| EPS | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Free Cash Flow | 54.87M | 9.33M | (91.05M) | (120.41M) | (151.78M) | (89.30M) | (39.64M) | (7.87M) |
| FCF / Share | 1.09 | 0.20 | -2.23 | -3.56 | -5.01 | -3.54 | -1.72 | -0.34 |
| Operating CF | 55.83M | 10.32M | (70.94M) | (120.14M) | (132.76M) | (89.08M) | (39.36M) | (373,000) |
| Total Assets | 842.81M | 670.75M | 646.62M | 352.91M | 294.65M | 240.86M | 146.71M | 51.98M |
| Total Debt | 319.45M | 317.76M | 308.14M | 2.19M | 2.61M | 3.26M | 3.65M | 0 |
| Cash & Equiv | 296.68M | 222.50M | 286.33M | 28.00M | 31.34M | 142.09M | 11.97M | 51.96M |
| Book Value | 314.69M | 225.64M | 248.67M | 142.04M | 120.21M | 172.09M | 130.35M | (10.32M) |
| Return on Equity | -0.07 | -0.39 | -0.66 | -0.96 | -0.70 | -0.60 | -0.40 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.24M | 159.88M | 148.93M | 133.01M | 127.78M | 111.58M | 99.41M | 90.38M | 77.88M | 69.22M | 69.55M | 47.73M |
| Net Income | (67.23M) | (790.15M) | (5.73M) | 2.90M | (5.86M) | (14.68M) | (23.79M) | (14.23M) | (24.64M) | (25.28M) | (35.66M) | (23.59M) |
| EPS | -1.06 | -13.43 | -0.12 | 0.05 | -0.12 | -0.30 | -0.49 | -0.30 | -0.52 | -0.54 | -0.71 | -0.57 |
| Free Cash Flow | (273.70M) | (229.43M) | 5.47M | 39.49M | 11.91M | (2.00M) | (5.09M) | (6.20M) | (14.58M) | 15.20M | (21.62M) | (18.22M) |
| FCF / Share | -4.32 | -3.90 | 0.11 | 0.69 | 0.24 | -0.04 | -0.11 | -0.13 | -0.31 | 0.32 | -0.46 | -0.44 |
| Operating CF | (273.01M) | (228.76M) | 6.07M | 39.68M | 12.04M | (1.96M) | (5.07M) | 3.98M | (3.80M) | 15.21M | (16.62M) | (18.22M) |
| Total Assets | 1.04B | 890.92M | 842.81M | 785.12M | 725.83M | 690.25M | 670.75M | 667.89M | 660.75M | 651.96M | 646.62M | 650.64M |
| Total Debt | 760.54M | 323.78M | 319.45M | 318.76M | 318.90M | 317.16M | 317.76M | 317.65M | 316.56M | 307.52M | 308.14M | 307.97M |
| Cash & Equiv | 330.73M | 324.91M | 296.68M | 282.02M | 228.12M | 211.82M | 222.50M | 222.97M | 233.25M | 302.84M | 286.33M | 303.06M |
| Book Value | (10.42M) | 242.49M | 314.69M | 292.05M | 255.16M | 233.26M | 225.64M | 232.02M | 228.99M | 234.60M | 248.67M | 269.08M |
| Return on Equity | N/A | -3.26 | -0.02 | 0.01 | -0.02 | -0.06 | -0.11 | -0.06 | -0.11 | -0.11 | -0.14 | -0.09 |
MIRM News
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM
Deutsche Bank AG Purchases New Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals Q2 Earnings Call Highlights
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates